Skip to main content
NASDAQ:TBPH

Theravance Biopharma Competitors

$18.87
+0.33 (+1.78 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.09
$18.99
50-Day Range
$18.54
$22.46
52-Week Range
$14.48
$28.98
Volume473,759 shs
Average Volume333,855 shs
Market Capitalization$1.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94

Competitors

Theravance Biopharma (NASDAQ:TBPH) Vs. GLPG, IMAB, SAGE, BHVN, SDGR, and LEGN

Should you be buying TBPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Theravance Biopharma, including Galapagos (GLPG), I-Mab (IMAB), Sage Therapeutics (SAGE), Biohaven Pharmaceutical (BHVN), Schrödinger (SDGR), and Legend Biotech (LEGN).

Theravance Biopharma (NASDAQ:TBPH) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Risk and Volatility

Theravance Biopharma has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Institutional & Insider Ownership

80.4% of Theravance Biopharma shares are held by institutional investors. Comparatively, 11.2% of Galapagos shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by insiders. Comparatively, 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Theravance Biopharma and Galapagos' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theravance Biopharma$73.41 million16.78$-236,460,000.00($4.25)-4.44
Galapagos$1.00 billion4.84$167.83 million$5.4613.58

Galapagos has higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theravance Biopharma and Galapagos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theravance Biopharma-345.16%N/A-51.60%
Galapagos-70.67%-11.78%-5.58%

Analyst Ratings

This is a summary of recent recommendations for Theravance Biopharma and Galapagos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theravance Biopharma00803.00
Galapagos210602.22

Theravance Biopharma presently has a consensus price target of $33.1429, suggesting a potential upside of 75.64%. Galapagos has a consensus price target of $143.8182, suggesting a potential upside of 93.98%. Given Galapagos' higher probable upside, analysts plainly believe Galapagos is more favorable than Theravance Biopharma.

Summary

Theravance Biopharma beats Galapagos on 8 of the 14 factors compared between the two stocks.

I-Mab (NASDAQ:IMAB) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Analyst Ratings

This is a breakdown of current recommendations for I-Mab and Theravance Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
I-Mab00403.00
Theravance Biopharma00803.00

I-Mab presently has a consensus price target of $70.00, suggesting a potential upside of 12.78%. Theravance Biopharma has a consensus price target of $33.1429, suggesting a potential upside of 75.64%. Given Theravance Biopharma's higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than I-Mab.

Insider & Institutional Ownership

16.6% of I-Mab shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares I-Mab and Theravance Biopharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-Mab$4.31 million1,042.73$-208,560,000.00($28.90)-2.15
Theravance Biopharma$73.41 million16.78$-236,460,000.00($4.25)-4.44

I-Mab has higher earnings, but lower revenue than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares I-Mab and Theravance Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
I-MabN/AN/AN/A
Theravance Biopharma-345.16%N/A-51.60%

Summary

Theravance Biopharma beats I-Mab on 6 of the 11 factors compared between the two stocks.

Theravance Biopharma (NASDAQ:TBPH) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Theravance Biopharma and Sage Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theravance Biopharma00803.00
Sage Therapeutics07802.53

Theravance Biopharma presently has a consensus price target of $33.1429, indicating a potential upside of 75.64%. Sage Therapeutics has a consensus price target of $89.8667, indicating a potential upside of 21.64%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Theravance Biopharma is more favorable than Sage Therapeutics.

Profitability

This table compares Theravance Biopharma and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theravance Biopharma-345.16%N/A-51.60%
Sage Therapeutics-7,706.84%-63.81%-56.64%

Risk and Volatility

Theravance Biopharma has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500.

Institutional and Insider Ownership

80.4% of Theravance Biopharma shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by company insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Theravance Biopharma and Sage Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theravance Biopharma$73.41 million16.78$-236,460,000.00($4.25)-4.44
Sage Therapeutics$6.87 million628.89$-680,240,000.00($13.38)-5.52

Theravance Biopharma has higher revenue and earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Theravance Biopharma beats Sage Therapeutics on 11 of the 13 factors compared between the two stocks.

Biohaven Pharmaceutical (NYSE:BHVN) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Risk and Volatility

Biohaven Pharmaceutical has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Earnings and Valuation

This table compares Biohaven Pharmaceutical and Theravance Biopharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.26
Theravance Biopharma$73.41 million16.78$-236,460,000.00($4.25)-4.44

Theravance Biopharma has higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Biohaven Pharmaceutical and Theravance Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical011002.91
Theravance Biopharma00803.00

Biohaven Pharmaceutical presently has a consensus target price of $99.50, indicating a potential upside of 45.74%. Theravance Biopharma has a consensus target price of $33.1429, indicating a potential upside of 75.64%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Theravance Biopharma is more favorable than Biohaven Pharmaceutical.

Profitability

This table compares Biohaven Pharmaceutical and Theravance Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Theravance Biopharma-345.16%N/A-51.60%

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by insiders. Comparatively, 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Theravance Biopharma beats Biohaven Pharmaceutical on 8 of the 13 factors compared between the two stocks.

Theravance Biopharma (NASDAQ:TBPH) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Insider and Institutional Ownership

80.4% of Theravance Biopharma shares are held by institutional investors. Comparatively, 41.3% of Schrödinger shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Theravance Biopharma and Schrödinger's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theravance Biopharma-345.16%N/A-51.60%
Schrödinger-19.92%-7.25%-5.33%

Analyst Ratings

This is a summary of recent recommendations and price targets for Theravance Biopharma and Schrödinger, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theravance Biopharma00803.00
Schrödinger01302.75

Theravance Biopharma presently has a consensus price target of $33.1429, indicating a potential upside of 75.64%. Schrödinger has a consensus price target of $84.00, indicating a potential upside of 40.75%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than Schrödinger.

Valuation & Earnings

This table compares Theravance Biopharma and Schrödinger's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theravance Biopharma$73.41 million16.78$-236,460,000.00($4.25)-4.44
Schrödinger$85.54 million48.85$-24,570,000.00N/AN/A

Schrödinger has higher revenue and earnings than Theravance Biopharma.

Summary

Theravance Biopharma beats Schrödinger on 6 of the 11 factors compared between the two stocks.

Legend Biotech (NASDAQ:LEGN) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

18.9% of Legend Biotech shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Legend Biotech and Theravance Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Legend Biotech-543.73%-205.60%-43.03%
Theravance Biopharma-345.16%N/A-51.60%

Earnings & Valuation

This table compares Legend Biotech and Theravance Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$64.39 million62.69$-132,970,000.00N/AN/A
Theravance Biopharma$73.41 million16.78$-236,460,000.00($4.25)-4.44

Legend Biotech has higher earnings, but lower revenue than Theravance Biopharma.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Legend Biotech and Theravance Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Legend Biotech00303.00
Theravance Biopharma00803.00

Legend Biotech presently has a consensus price target of $49.00, suggesting a potential upside of 61.45%. Theravance Biopharma has a consensus price target of $33.1429, suggesting a potential upside of 75.64%. Given Theravance Biopharma's higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Legend Biotech.

Summary

Theravance Biopharma beats Legend Biotech on 7 of the 10 factors compared between the two stocks.


Theravance Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Galapagos logo
GLPG
Galapagos
1.3$74.14+0.7%$4.86 billion$1.00 billion-11.23Analyst Report
Gap Down
I-Mab logo
IMAB
I-Mab
1.2$62.07+5.3%$4.49 billion$4.31 million-2.15
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$73.88+0.4%$4.32 billion$6.87 million-7.14Analyst Revision
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$68.27+3.2%$4.24 billionN/A-5.56Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.6$59.68+3.5%$4.18 billion$85.54 million0.00Analyst Report
News Coverage
LEGN
Legend Biotech
1.3$30.35+2.7%$4.04 billion$64.39 million0.00
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.59+0.1%$3.75 billionN/A-6.28
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.23+2.4%$3.72 billion$806.43 million-8.67Analyst Revision
Alkermes logo
ALKS
Alkermes
1.2$22.44+0.4%$3.60 billion$1.17 billion-48.78Insider Selling
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$23.70+7.7%$3.53 billion$204.89 million-29.63High Trading Volume
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.83+4.5%$3.50 billion$339.08 million-12.69Analyst Report
Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.68+0.4%$3.41 billionN/A-57.55Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.57+3.9%$3.39 billion$114.62 million-7.49Earnings Announcement
Analyst Report
Analyst Revision
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$54.32+3.4%$3.34 billion$117.91 million-11.02
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$65.94+1.5%$3.24 billionN/A-18.79Earnings Announcement
Analyst Upgrade
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$58.60+0.3%$3.14 billion$1.11 billion18.84Analyst Report
Arvinas logo
ARVN
Arvinas
1.7$63.01+2.7%$3.09 billion$42.98 million-24.61
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.54+1.1%$3.05 billion$60,000.00-11.66Earnings Announcement
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$81.62+1.8%$2.95 billion$26.52 million-7.19Earnings Announcement
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.14+0.1%$2.76 billion$644.77 million-10.29Upcoming Earnings
Insmed logo
INSM
Insmed
1.2$26.46+1.9%$2.74 billion$136.47 million-10.18Earnings Announcement
Analyst Report
High Trading Volume
Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.98+2.0%$2.73 billion$421.03 million21.82Analyst Report
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.29+1.2%$2.70 billion$306.98 million-5.48
MorphoSys logo
MOR
MorphoSys
0.3$19.95+2.0%$2.62 billion$80.43 million95.00News Coverage
Gap Down
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$41.61+1.1%$2.57 billionN/A-22.86Earnings Announcement
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.22+4.1%$2.45 billion$182.24 million-8.02Earnings Announcement
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$58.91+2.1%$2.43 billionN/A0.00
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.7$20.61+0.8%$2.40 billion$306.49 million23.16Earnings Announcement
Cryoport logo
CYRX
Cryoport
1.7$51.27+10.3%$2.34 billion$33.94 million-88.40Analyst Report
Analyst Revision
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$46.61+1.1%$2.33 billion$963.01 million14.48Earnings Announcement
Analyst Report
Analyst Revision
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.8$36.60+3.3%$2.28 billion$2.11 million-7.92Analyst Report
Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$3.33+2.7%$2.23 billion$901.90 million-18.50Insider Buying
Xencor logo
XNCR
Xencor
1.6$37.92+1.8%$2.21 billion$156.70 million-27.09Earnings Announcement
Analyst Report
Analyst Revision
Organogenesis logo
ORGO
Organogenesis
1.0$17.18+4.3%$2.20 billion$260.98 million-286.33Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$132.71+0.1%$2.20 billionN/A-11.99Earnings Announcement
Analyst Revision
ALX Oncology logo
ALXO
ALX Oncology
1.9$54.68+10.8%$2.20 billionN/A0.00
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$27.92+2.9%$2.15 billion$103.54 million-20.99Earnings Announcement
Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$57.01+0.0%$2.14 billionN/A-21.19Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$65.90+0.3%$2.11 billionN/A-28.04Earnings Announcement
News Coverage
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$125.35+4.1%$2.09 billion$120.28 million-126.62Analyst Report
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.7$29.15+1.4%$2.07 billion$15 million-15.26Analyst Downgrade
Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.93+2.1%$1.99 billion$410,000.00-6.07Earnings Announcement
Analyst Report
News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$25.72+4.4%$1.98 billion$23.90 million-15.98Earnings Announcement
Analyst Revision
FibroGen logo
FGEN
FibroGen
1.8$21.13+4.6%$1.95 billion$256.58 million-8.10Earnings Announcement
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.98+6.2%$1.92 billion$34.51 million-17.93Analyst Report
News Coverage
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$33.01+1.6%$1.91 billion$25 million-6.60Analyst Report
Analyst Revision
News Coverage
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$20.67+4.4%$1.88 billionN/A-7.36Earnings Announcement
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.16+1.5%$1.80 billion$428.41 million16.17Earnings Announcement
Morphic logo
MORF
Morphic
1.5$49.25+2.7%$1.78 billion$16.98 million-31.57Analyst Report
Gap Down
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00+0.0%$1.77 billion$14.87 million-14.18
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.